RxDoctor Payments Data

Gina Facciolo, DO

Family Medicine · Hockessin, DENPI 1346532017

Payments from drug & device makers

$684in general payments, 2019–2025

Across 33 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$265
  • Amgen$58
  • AstraZeneca$55
  • Takeda Pharmaceuticals U.S.A., Inc.$48
  • Lilly USA, LLC$48
  • Novo Nordisk$41
  • plus $170 from 7 others

What the payments were for

  • Food & beverage$66898%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$684 in reported general payments places this provider in the 65th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$174,375
Medicare patients
398
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$186,611
MounjaroTirzepatide42$72,765
TrulicityDulaglutide23$43,213
JardianceEmpagliflozin24$40,015
RybelsusSemaglutide11$26,643
JanuviaSitagliptin Phosphate17$26,319
FarxigaDapagliflozin Propanediol25$25,300
EliquisApixaban18$16,196
MyrbetriqMirabegron11$14,182
EntrestoSacubitril/Valsartan12$7,754
Breo ElliptaFluticasone/Vilanterol15$7,480
SymbicortBudesonide/Formoterol Fumarate16$6,248
Atorvastatin Calcium460$5,160
Levothyroxine Sodium276$3,347
Gabapentin121$3,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$41$213,255150 claims
Lilly USA, LLCMounjaro, Trulicity$48$115,97865 claims
AstraZenecaFarxiga, Symbicort$55$31,54841 claims
MerckJanuvia$29$26,31917 claims
PfizerEliquis$34$16,19618 claims
Astellas Pharma US IncMyrbetriq$18$14,18211 claims
GSKBreo Ellipta$31$7,48015 claims
AbbVieSynthroid$11$2,74575 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 352 family medicine providers in Delaware.

Other family medicine in Hockessin

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →